“ULTRASOUND-RESPONSIVEPLGANANOBUBBLESFORIMPROVEDORAL BIOAVAILABILITY OF ENZALUTAMIDE: FORMULATION OPTIMIZATION AND PHARMACOKINETIC EVALUATION”
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Poor aqueous solubility and low oral bioavailability limit the therapeutic effectiveness of enzalutamide, a second-generation androgen receptor inhibitor used in advanced prostate cancer. This study aimed to develop and optimize ultrasound-responsive PLGA nanobubbles to enhance oraldelivery andpharmacokinetic performance. Nanobubbles werepreparedusing thesolventevaporationmethodandoptimizedviaaBox–Behnkendesign,evaluating the effect of formulation variables on key quality attributes. The optimized formulation exhibited a particlesizeof193.5 ±2.8 nm, polydispersity index of 0.26± 0.016,zetapotential of−31.4± 1.17 mV, and entrapment efficiency of 65.12 ± 2.54%. Characterization by FTIR, DSC, and XRD confirmed drug–polymer compatibility, and SEM revealed uniform spherical morphology. In vitro studies showed sustained and ultrasound-triggered drug release. In vivo evaluationinWistarratsdemonstratedsignificantincreasesinC_maxandAUC₀–t,confirming enhanced oral absorption and prolonged systemic exposure. These results indicate that ultrasound-responsive PLGA nanobubbles are a promising oral delivery platform for poorly soluble anticancer drugs.
Fields of Study & Subjects
Drug Solubulity and Delivery Systems
Advanced Drug Delivery Systems
Nanoparticle-Based Drug Delivery
Publication details
- Journal / source
- Journal of Bio Innovation
- Volume
- 15
- Issue
- 1
- Pages
- 205–233
- Publication date
- 30 January 2026
- Language
- EN